Africa and Middle East Cardiovascular Epidemiological Study
NCT ID: NCT01243138
Last Updated: 2021-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
4386 participants
OBSERVATIONAL
2011-07-31
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
European Study of Cardiovascular Risk
NCT00882336
Risk Factors in Young Middle Eastern Women With Cardiovascular Disease
NCT04975503
Study on Nutrition and Cardiovascular Risk in Spain.
NCT01133093
Cardiovascular Epidemiology in Russian Federation
NCT02449460
Atherosclerosis Risk in Communities (ARIC)
NCT00005131
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects presenting with any life threatening disease/condition
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Algiers, , Algeria
Pfizer Investigational Site
Bejaja, , Algeria
Pfizer Investigational Site
Djelfa, , Algeria
Pfizer Investigational Site
Laghouat, , Algeria
Pfizer Investigational Site
M'Sila, , Algeria
Pfizer Investigational Site
Relizane, , Algeria
Pfizer Investigational Site
Saïda, , Algeria
Pfizer Investigational Site
Tébessa, , Algeria
Pfizer Investigational Site
Tlemcen, , Algeria
Pfizer Investigational Site
Yaoundé, Cite Verte, Cameroon
Pfizer Investigational Site
Douala, Deido, Cameroon
Pfizer Investigational Site
Bafoussam, , Cameroon
Pfizer Investigational Site
Mbandjok, , Cameroon
Pfizer Investigational Site
Njombé, , Cameroon
Pfizer Investigational Site
Okoa, , Cameroon
Pfizer Investigational Site
Alexandria, , Egypt
Pfizer Investigational Site
Cairo, , Egypt
Pfizer Investigational Site
Shiben Al Kom, , Egypt
Pfizer Investigational Site
Tanta, , Egypt
Pfizer Investigational Site
Accra, , Ghana
Pfizer Investigational Site
Jachie-Ashanti, , Ghana
Pfizer Investigational Site
Kumasi, , Ghana
Pfizer Investigational Site
Sogakope V/R, , Ghana
Pfizer Investigational Site
Takoradze, , Ghana
Pfizer Investigational Site
Amman, , Jordan
Pfizer Investigational Site
Irbid, , Jordan
Pfizer Investigational Site
Salt, , Jordan
Pfizer Investigational Site
Chongoria, , Kenya
Pfizer Investigational Site
Nairobi, , Kenya
Pfizer Investigational Site
Adailiya, , Kuwait
Pfizer Investigational Site
Al Faḩāḩīl, , Kuwait
Pfizer Investigational Site
Kuwait City, , Kuwait
Pfizer Investigational Site
Mishrif, , Kuwait
Pfizer Investigational Site
Qadesya, , Kuwait
Pfizer Investigational Site
Yarmouk, , Kuwait
Pfizer Investigational Site
Jbeil, Lebanon, Lebanon, Lebanon
Pfizer Investigational Site
Beirut, , Lebanon
Pfizer Investigational Site
Jounieh, , Lebanon
Pfizer Investigational Site
Tripoli, , Lebanon
Pfizer Investigational Site
Abuja, FCT, , Nigeria
Pfizer Investigational Site
Abuja, Garki, , Nigeria
Pfizer Investigational Site
Calabar, , Nigeria
Pfizer Investigational Site
Enugu, , Nigeria
Pfizer Investigational Site
Keffi, Nassarawa, , Nigeria
Pfizer Investigational Site
Dammam, , Saudi Arabia
Pfizer Investigational Site
Jeddah, , Saudi Arabia
Pfizer Investigational Site
Mecca, , Saudi Arabia
Pfizer Investigational Site
Riyadh, , Saudi Arabia
Pfizer Investigational Site
Riyadh, , Saudi Arabia
Pfizer Investigational Site
Yanbu, , Saudi Arabia
Pfizer Investigational Site
Dakar, Nabil Choucair, Senegal
Pfizer Investigational Site
Dakar, Ouakam, Senegal
Pfizer Investigational Site
Kedoungou, , Senegal
Pfizer Investigational Site
Kébémer, , Senegal
Pfizer Investigational Site
Saint-Louis, , Senegal
Pfizer Investigational Site
Ziguinchor, , Senegal
Pfizer Investigational Site
Halfway House, Gauteng, South Africa
Pfizer Investigational Site
Sydenham, Durban, KwaZulu-Natal, South Africa
Pfizer Investigational Site
Mokopane, Limpopo, South Africa
Pfizer Investigational Site
Sheshego, Limpopo, South Africa
Pfizer Investigational Site
Mamelodi East, Pretoria, South Africa
Pfizer Investigational Site
Kwa-Zulu Natal, , South Africa
Pfizer Investigational Site
Rondebosch, , South Africa
Pfizer Investigational Site
Aryanah, , Tunisia
Pfizer Investigational Site
Bouficha, , Tunisia
Pfizer Investigational Site
Messaadine, , Tunisia
Pfizer Investigational Site
Sfax, , Tunisia
Pfizer Investigational Site
Tunis, , Tunisia
Pfizer Investigational Site
Zaghouan, , Tunisia
Pfizer Investigational Site
Abu Dhabi, , United Arab Emirates
Pfizer Investigational Site
Al Ain City, , United Arab Emirates
Pfizer Investigational Site
Dubai, , United Arab Emirates
Pfizer Investigational Site
Ras Al Khaima, , United Arab Emirates
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hamoui O, Omar MI, Raal FJ, Rashed W, Kane A, Alami M, Abreu P, Mashhoud W, Alsheikh-Ali AA. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study. BMC Cardiovasc Disord. 2019 Mar 15;19(1):61. doi: 10.1186/s12872-019-1034-2.
Brouri M, Ouadahi N, Nibouche D, Benabbas Y, El Hassar M, Bouraoui S, Abad N, Abreu PC, Ikardouchene L. [Cardiovascular risk factors in Algeria. Analysis of the subgroup from the "Africa/Middle East Cardiovascular Epidemiological" Study]. Ann Cardiol Angeiol (Paris). 2018 Apr;67(2):61-66. doi: 10.1016/j.ancard.2018.01.003. Epub 2018 Mar 9. French.
Raal FJ, Alsheikh-Ali AA, Omar MI, Rashed W, Hamoui O, Kane A, Alami M, Abreu P, Mashhoud WM. Cardiovascular risk factor burden in Africa and the Middle East across country income categories: a post hoc analysis of the cross-sectional Africa Middle East Cardiovascular Epidemiological (ACE) study. Arch Public Health. 2018 Feb 12;76:15. doi: 10.1186/s13690-018-0257-5. eCollection 2018.
Ahmed AM, Hersi A, Mashhoud W, Arafah MR, Abreu PC, Al Rowaily MA, Al-Mallah MH. Cardiovascular risk factors burden in Saudi Arabia: The Africa Middle East Cardiovascular Epidemiological (ACE) study. J Saudi Heart Assoc. 2017 Oct;29(4):235-243. doi: 10.1016/j.jsha.2017.03.004. Epub 2017 Mar 14.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2581186
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.